UCLA Jonsson Comprehensive Cancer Center researchers found that treating women with HER2 positive metastatic breast cancer with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly mitigates disease progression, compared to the current standard of care, trastuzumab emtansine (T-DM1).
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
